目的 探討枳術(shù)寬中膠囊聯(lián)合蘭索拉唑和莫沙必利治療反流性食管炎的臨床療效。方法 選取2014年9月-2015年9月在郫縣人民醫(yī)院接受治療的反流性食管炎患者106例，按照治療方法的差別分成對照組和治療組，每組各53例。對照組患者口服枸櫞酸莫沙必利片，5 mg/次，3次/d；同時口服蘭索拉唑腸溶片，20 mg/次，2次/d；治療組在對照組基礎(chǔ)上口服枳術(shù)寬中膠囊，3粒/次，3次/d。兩組患者均治療8周。觀察兩組的臨床療效，比較兩組患者的臨床癥狀和生活質(zhì)量情況。結(jié)果 治療后，對照組和治療組的總有效率分別為81.13%、94.34%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者燒心、反酸、胸骨后疼痛評分均顯著下降，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的降低程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的生理功能、生理職能、身體疼痛、總體健康、生命活力、社會職能、情感職能及精神健康評分均顯著升高，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的升高程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 枳術(shù)寬中膠囊聯(lián)合蘭索拉唑和莫沙必利治療反流性食管炎具有較好的臨床療效，能明顯改善患者的臨床癥狀，提高患者的生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Zhizhu Kuanzhong Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis. Methods Patients (106 cases) with reflux esophagitis in Pixian People's Hospital from September 2014 to September 2015 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into the control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Mosapride Citrate Tablets, 5 mg/time, three times daily. And patients in the control group were also po administered with Lansoprazole Enteric-coated Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Zhizhu Kuanzhong Capsules on the basis of the control group, 3 grains/time, three times daily. After treatment, the clinical efficacies were evaluated, and clinical symptom and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 94.34%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of heartburn, acid regurgitation, and retrosternal pain in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the scores of physiological function, physiological role, body ache, general health, life vigor, social function, emotional role, and mental health in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhizhu Kuanzhong Capsules combined with lansoprazole and mosapride has clinical curative effect in treatment of reflux esophagitis, and can improve clinical symptoms, enhance quality of life, which has a certain clinical application value.